List of Excipients in Branded Drug KEPIVANCE

Kepivance Excipient Strategy and Commercial Opportunities for Palifermin

Last updated: September 2, 2026

Kepivance is a lyophilized recombinant human keratinocyte growth factor, palifermin, approved by the FDA to reduce the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy followed by autologous hematopoietic stem-cell support.[1] Its formulation uses a conventional protein-stabilization platform: histidine buffer, sucrose, mannitol, and polysorbate 80. The largest commercial opportunities are improved handling, reduced preparation time, alternative presentations, biosimilar-compatible excipient systems, and hospital supply integration rather than a simple substitution of one inactive ingredient.

Kepivance has limited small-molecule generic exposure because palifermin is a biologic. The relevant competitive pathway is a biosimilar or interchangeable biologic under the Public Health Service Act, combined with formulation, manufacturing, device, and clinical-use differentiation.[2]

What excipients are used in Kepivance?

Kepivance contains four principal formulation excipients: L-histidine, mannitol, sucrose, and polysorbate 80. The product is supplied as a sterile, preservative-free, single-dose lyophilized powder in a 6.25 mg vial.[1]

Formulation element	Function in Kepivance	Commercial relevance
L-histidine	pH control and buffering during manufacture, storage, and reconstitution	Supports protein stability; creates opportunity for buffer optimization
Sucrose	Lyoprotectant and protein-stabilizing sugar	Important for preserving tertiary structure during freezing and drying
Mannitol	Bulking agent and cake-structure aid	Supports an acceptable lyophilized cake and handling performance
Polysorbate 80	Surfactant that reduces adsorption and interfacial aggregation	Creates opportunities for oxidation control and alternative surfactant systems
Sterile Water for Injection	Reconstitution vehicle supplied separately	Drives preparation time, pharmacy workflow, and container-closure requirements

The formulation is reconstituted with Sterile Water for Injection to produce a solution for intravenous administration. The approved dose is 60 micrograms per kilogram per day, administered for three consecutive days before myelotoxic therapy and three consecutive days after therapy.[1]

How does the Kepivance formulation work?

The excipient system addresses the main stability risks associated with a recombinant protein: pH drift, aggregation, adsorption to surfaces, freeze-drying stress, and loss of activity during reconstitution.

Histidine buffer

Histidine is widely used in biologics because it provides buffering near mildly acidic pH values and generally has a favorable compatibility profile with proteins. For palifermin, histidine helps control the chemical environment during lyophilization and storage.

Potential development variables include:

• Histidine concentration.
• Final pH.
• Histidine versus phosphate or citrate buffering.
• Buffer capacity after reconstitution.
• Compatibility with container-closure materials.
• Impact on aggregation and biological activity.

A commercial reformulation would need to show that any buffer change preserves palifermin potency, purity, higher-order structure, and immunogenicity profile.

Sucrose

Sucrose is a standard lyoprotectant for protein therapeutics. During freezing and drying, it can replace some of the hydrogen-bonding interactions lost by the protein and limit structural damage. It also reduces aggregation during reconstitution.

The main opportunity is not the use of sucrose itself. It is the optimization of the sucrose-to-mannitol ratio and the interaction of the sugar with the protein, vial, and drying cycle.

Mannitol

Mannitol contributes bulk and helps form a visually acceptable lyophilized cake. It can improve vial presentation and facilitate manufacturing, but its crystallization behavior must be controlled because crystallization can alter the distribution and protective effect of sucrose.

A stronger formulation program would evaluate:

• Mannitol concentration.
• Mannitol crystallinity.
• Cake collapse temperature.
• Residual moisture.
• Reconstitution time.
• Palifermin recovery after extended storage.

Polysorbate 80

Polysorbate 80 limits protein adsorption to vial and administration surfaces and reduces aggregation caused by agitation or air-liquid interfaces. Its principal risks are hydrolysis, oxidation, peroxide formation, and interaction with trace metals or packaging components.

For palifermin, polysorbate 80 is a meaningful development target because a biologic formulation can lose quality even when the active protein concentration remains within specification. Commercial work may focus on:

• Low-peroxide polysorbate 80.
• Polysorbate 20 substitution.
• Nonionic surfactants with improved oxidative stability.
• Surfactant concentration reduction.
• Protein-compatible antioxidant or metal-control strategies.
• Container and tubing compatibility.

Any surfactant change would require a comparability package covering aggregates, subvisible particles, potency, degradation products, and anti-drug antibodies.

What is the FDA regulatory status of Kepivance?

Kepivance was approved by the FDA in February 2005 under the biologics framework for use in adults with hematologic malignancies receiving myelotoxic therapy associated with a high incidence of severe oral mucositis.[1]

Regulatory item	Kepivance status
Active ingredient	Palifermin
Product type	Recombinant protein biologic
FDA approval	2005
Dosage form	Lyophilized powder for injection
Strength	6.25 mg per vial
Route	Intravenous
Approved use	Reduction of severe oral mucositis in specified hematologic malignancy and stem-cell-support settings
Administration schedule	Three days before and three days after myelotoxic therapy
Preservative	None
Administration limitation	Not administered within 24 hours before, during, or within 24 hours after myelotoxic therapy
Reference product pathway	351(a) biologic; biosimilar pathway under section 351(k)

Kepivance is not a conventional small-molecule product listed through the FDA Orange Book framework. Biologic competition is evaluated through the FDA Purple Book and the 351(k) biosimilar pathway.[2] The product’s commercial exclusivity is therefore governed by biologic reference-product exclusivity and patent rights rather than the five-year New Chemical Entity exclusivity used for small molecules.

When does Kepivance lose exclusivity?

Kepivance’s original regulatory exclusivity period has expired. The reference-product exclusivity period for a licensed biologic is 12 years from first licensure under the Biologics Price Competition and Innovation Act, subject to statutory rules and exclusivity determinations.[3]

Exclusivity category	Commercial position
FDA reference-product exclusivity	Expired
Small-molecule Orange Book exclusivity	Not applicable
Biosimilar competition	Legally available through section 351(k)
Patent blocking risk	Depends on unexpired composition, formulation, manufacturing, or use claims
Pediatric exclusivity	No current commercial extension identified in the FDA label
Generic substitution	Not applicable as an automatic small-molecule substitution

Kepivance therefore has a mature reference-product profile. A competitor would not need to wait for the original biologic exclusivity period to expire, but would still need to address patent litigation, manufacturing comparability, clinical development, and regulatory requirements.

What patents protect Kepivance and palifermin?

The practical patent estate for palifermin can include several claim categories:

1. Palifermin composition claims.
2. Recombinant production and purification claims.
3. Protein sequence or variant claims.
4. Lyophilized formulation claims.
5. Stabilized aqueous formulation claims.
6. Methods for reducing oral mucositis.
7. Dosing and treatment-timing claims.
8. Container-closure and delivery claims.

The earliest palifermin and keratinocyte-growth-factor patent families were filed decades ago. Core composition and foundational use claims are therefore expected to provide less blocking leverage than later formulation, manufacturing, or dosing patents. The strongest current barriers are likely to be technical rather than basic molecule ownership: expression-cell performance, purification, aggregation control, potency assays, and clinical comparability.

What formulation patents could matter?

Formulation claims may cover:

• Specific histidine concentrations and pH ranges.
• Defined ratios of sucrose and mannitol.
• Polysorbate 80 concentration ranges.
• Lyophilized cakes with defined residual moisture.
• Reconstitution time or protein recovery.
• Stabilized liquid palifermin.
• Reduced-aggregate compositions.
• Container systems that limit adsorption or oxidation.

A biosimilar developer should not assume that expiration of the original palifermin composition patent eliminates formulation risk. A later patent can remain relevant if it claims a specific excipient range, lyophilization cycle, reconstituted concentration, or storage condition.

How strong is the Kepivance patent estate?

The estate is structurally mature but potentially complex. Foundational molecule and use claims have limited remaining commercial life because palifermin was approved in 2005. Later patents can still create narrower barriers around formulation and manufacturing.

Patent category	Expected strategic value
Core palifermin molecule	Low to moderate for new entrants if foundational claims have expired
Protein sequence variants	Moderate, depending on claim scope and biosimilar sequence
Lyophilized formulation	Moderate to high if claims cover the marketed excipient system
Liquid formulation	High for a reformulated product, if valid and unexpired
Manufacturing process	High when difficult to design around or tied to product quality
Method of use	Moderate, with value depending on patient population and dosing claims
Delivery device	Low for the current vial presentation; higher for ready-to-use systems
Trade secrets	High where purification, refolding, aggregation control, or potency testing is difficult to replicate

Patent strength should be measured claim by claim. A broad palifermin claim may be weak against a biosimilar if expired, while a narrow manufacturing claim may still delay market entry if the process is difficult to replace without extensive comparability work.

What Paragraph IV or biosimilar challenges affect Kepivance?

A traditional Paragraph IV certification is associated with an Abbreviated New Drug Application and small-molecule Orange Book patents. Kepivance is a biologic, so a biosimilar applicant would generally use the section 351(k) pathway and the patent-exchange process under the Biologics Price Competition and Innovation Act.[2,4]

A competitive applicant would likely pursue one of three strategies:

Full biosimilar

The applicant would demonstrate high similarity to palifermin using analytical, functional, pharmacokinetic, immunogenicity, and clinical data. This approach offers the broadest commercial positioning but requires substantial manufacturing and comparability investment.

Formulation-led biosimilar

The applicant would retain the palifermin sequence while modifying the excipient system, presentation, or reconstitution process. This could reduce dependence on the originator formulation but may create new formulation patents and additional comparability questions.

Reference-adjacent biologic

The applicant could develop a palifermin product with a distinct formulation, device, or administration workflow. This may avoid selected formulation claims but would face greater differentiation and clinical adoption requirements.

No automatic pharmacy substitution should be assumed unless the FDA grants interchangeable status. Hospital use may still shift through formulary decisions, contracting, price concessions, and procurement systems.

What commercial opportunities exist in Kepivance excipients?

Ready-to-use liquid palifermin

A stable liquid presentation could eliminate or reduce reconstitution steps. The commercial advantages would include:

• Lower pharmacy labor.
• Fewer reconstitution errors.
• Faster administration.
• Reduced risk of particulate formation during preparation.
• Easier integration into oncology treatment protocols.

The technical challenge is long-term liquid stability. A liquid product must control aggregation, oxidation, adsorption, microbial risk, and container interaction without relying on a preservative.

Dual-chamber or integrated reconstitution packaging

A vial-and-diluent or dual-chamber system could preserve the lyophilized product while simplifying preparation. Such a system may have value even if the active formulation remains unchanged.

Potential claims could cover:

• Integrated sterile diluent.
• Transfer systems.
• Reconstitution adapters.
• Closed-system preparation.
• Premeasured diluent volume.
• Reduced product loss.

Alternative surfactant systems

Polysorbate degradation is a recurring concern in protein products. A competitor could evaluate polysorbate 20, improved polysorbate 80 grades, or alternative nonionic surfactants. The commercial benefit would depend on measurable improvements in stability, shipping tolerance, or shelf life.

Longer in-use stability

Kepivance’s short preparation and post-reconstitution handling window creates an opportunity for a product with longer validated in-use stability. This could help hospitals coordinate dosing across treatment units and reduce product waste.

Lower-waste vial sizes

The 6.25 mg vial may create dose-rounding and residual-waste issues because dosing is weight-based. Additional vial sizes or a higher-concentration presentation could improve dose efficiency for larger patients, although new strengths would require regulatory approval and manufacturing validation.

Cold-chain reduction

A formulation that tolerates wider temperature excursions or a less restrictive storage profile could reduce distribution costs. This opportunity is technically difficult because protein stability, not merely excipient selection, determines the final storage requirement.

What manufacturing and intellectual-property barriers exist?

Palifermin development requires more than matching excipient names. The critical manufacturing variables include:

• Host-cell expression.
• Protein folding and disulfide-bond control.
• Removal of host-cell proteins and DNA.
• Aggregation control.
• Glycosylation and post-translational characterization.
• Endotoxin and bioburden control.
• Potency assay reproducibility.
• Subvisible particle control.
• Lyophilization cycle robustness.
• Container-closure integrity.

A biosimilar applicant may match the qualitative excipient composition but still fail to achieve analytical similarity because the manufacturing process changes the product’s impurity profile, aggregate level, charge variants, or functional activity.

The most defensible commercial position is a combined formulation and manufacturing strategy. An excipient-only differentiation program is easier to design around and may not create durable market protection.

How does Kepivance compare with competing oral-mucositis products?

Kepivance occupies a narrow, high-acuity segment. It is used around myelotoxic therapy and stem-cell support rather than as a broad treatment for chemotherapy- or radiation-induced mucositis.

Product category	Active approach	Formulation opportunity	Competitive position
Kepivance	Recombinant growth factor, palifermin	Lyophilized protein, liquid reformulation, biosimilar	Targeted hematologic malignancy use
Oral rinses and supportive care	Local symptom management	Ready-to-use liquids, unit-dose packaging	Broad use, lower technical barrier
Cryotherapy	Local temperature reduction	Device and workflow optimization	Procedure-dependent
Photobiomodulation	Light-based mucosal support	Device and protocol differentiation	Specialized centers
Other biologic growth-factor strategies	Tissue-protective or regenerative mechanisms	Protein stabilization and delivery	Clinical and regulatory risk varies

Kepivance’s main advantage is a defined biologic mechanism and an approved use in a high-risk patient population. Its disadvantages include intravenous administration, dose timing restrictions, reconstitution, cold-chain dependence, and a limited treatment population.

What generic launch risks exist for Kepivance?

A biosimilar or follow-on launch would face five principal risks:

1. Clinical-market risk. The labeled population is narrow, limiting the addressable market.
2. Manufacturing risk. Protein quality attributes must remain highly comparable.
3. Formulation risk. A different excipient system can create new degradation or immunogenicity concerns.
4. Patent risk. Later formulation, manufacturing, or use claims may delay launch.
5. Procurement risk. Hospitals may require meaningful discounts before changing an established protocol.

The most credible launch sequence would begin with a palifermin biosimilar using the established lyophilized format, followed by a differentiated liquid or workflow product after market access and clinical adoption are established.

What is the revenue exposure and commercial market for Kepivance?

Public company reporting does not provide a reliable current standalone revenue figure for Kepivance. Commercial value is better assessed through treatment volume, vial consumption, reimbursement, and hospital utilization.

Relevant market drivers include:

• Number of autologous stem-cell transplants.
• Use of high-dose conditioning regimens.
• Incidence of severe oral mucositis.
• Hospital formulary placement.
• Payer coverage.
• Dose rounding and vial waste.
• Product acquisition cost.
• Reimbursement for supportive-care biologics.

The addressable market is smaller than the general oncology supportive-care market because the FDA indication is limited. The strongest commercial opportunity is therefore not mass-market volume. It is premium workflow value in transplant centers, where reduced mucositis severity, shorter preparation time, lower waste, and reliable supply can influence purchasing.

What licensing deals and partnerships could create value?

The most practical partnership structures would involve:

• A regional license for palifermin biosimilar development.
• Co-development with a biologics manufacturer that has lyophilization capacity.
• Excipient or surfactant licensing tied to improved protein stability.
• Contract manufacturing with a fill-finish provider.
• Hospital-system partnerships for ready-to-use presentation testing.
• Device licensing for closed-system reconstitution.
• Supply agreements with transplant-center purchasing groups.

A formulation company would obtain greater negotiating leverage if it owns data showing improved reconstitution time, lower aggregate formation, longer in-use stability, or reduced vial waste. Generic excipient substitution without product-specific performance data would have limited licensing value.

Key Takeaways

• Kepivance is a lyophilized palifermin biologic containing histidine, sucrose, mannitol, and polysorbate 80.
• The excipients provide buffering, lyoprotection, cake formation, and interfacial protection.
• Original biologic exclusivity has expired, making a 351(k) biosimilar pathway available.
• Orange Book generic substitution is not the relevant framework; the Purple Book and biologics patent procedures are more relevant.
• The strongest commercial opportunities are a stable liquid product, integrated reconstitution packaging, improved surfactant stability, longer in-use storage, and lower-waste presentations.
• Manufacturing comparability and clinical adoption are greater barriers than simple excipient selection.
• The market is narrow but commercially relevant in hematopoietic stem-cell transplant centers.
• Later formulation and manufacturing patents may remain more important than expired foundational palifermin claims.
• A successful follow-on product will need a combined biologic, formulation, manufacturing, and hospital-workflow strategy.

FAQs About Kepivance Excipient Strategy

Can polysorbate 80 be removed from Kepivance?

Yes, a development program could evaluate surfactant-free or alternative-surfactant formulations, but removal would require evidence that palifermin remains stable against adsorption, agitation, aggregation, and particle formation.

Could Kepivance be supplied as a prefilled syringe?

A prefilled syringe is technically possible but would require evaluation of protein adsorption, syringe-material compatibility, extractables and leachables, dose accuracy, sterility, and delivery-device performance.

Would a palifermin biosimilar use the same excipients as Kepivance?

It may, but it is not required to use an identical excipient system. The biosimilar must demonstrate that formulation differences do not create clinically meaningful differences in quality, safety, or effectiveness.[2]

Can mannitol and sucrose be replaced by trehalose?

Trehalose could be evaluated as an alternative lyoprotectant, but replacement would alter cake structure, residual moisture, reconstitution behavior, and protein stability. The resulting formulation may also create separate patent considerations.

What is the most valuable excipient innovation for Kepivance?

A formulation that provides validated liquid stability, reduced aggregation, longer in-use storage, and faster preparation would likely have greater commercial value than a minor change in buffer or bulking agent.

References

1. U.S. Food and Drug Administration. (2022). Kepivance (palifermin) prescribing information. Biovitrum AB.

2. U.S. Food and Drug Administration. (2015). Scientific considerations in demonstrating biosimilarity to a reference product: Guidance for industry. FDA.

3. U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, Pub. L. No. 111-148, §§ 7001-7003.

4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.